Esaxerenone治疗2型糖尿病合并微量白蛋白尿的疗效与安全性:随机双盲安慰剂对照II期试验
这项多中心随机双盲安慰剂对照II期试验纳入365例接受RAS抑制剂治疗的2型糖尿病合并微量白蛋白尿患者,随机接受Esaxerenone 0.625、1.25、2.5、5 mg/d或安慰剂治疗12周。结果显示1.25、2.5、5 mg/d剂量组尿白蛋白肌酐比分别较安慰剂显著降低38%、50%、56%(均P<0.001),主要药物相关不良事件为高钾血症且呈剂量依赖性。
要点
- Esaxerenone 1.25–5 mg/d联合RAS抑制剂12周显著降低2型糖尿病微量白蛋白尿患者的UACR。
- 2.5和5 mg/d组UACR缓解率21%,显著高于安慰剂组3%。
- 高钾血症是最常见药物相关不良事件,发生率随剂量增加。
核心结论
- 在持续RAS抑制剂治疗基础上加用Esaxerenone 1.25、2.5、5 mg/d治疗12周,可显著降低2型糖尿病合并微量白蛋白尿患者的UACR。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照II期试验,纳入365例接受RAS抑制剂治疗、UACR≥45至<300 mg/g且eGFR≥30 ml/min/1.73 m²的2型糖尿病合并微量白蛋白尿患者。
- 患者随机接受Esaxerenone 0.625、1.25、2.5、5 mg/d或安慰剂治疗12周,主要终点为基线至第12周UACR变化(末次观测值结转)。
主要发现
- 1.25、2.5、5 mg/d组UACR较安慰剂分别降低38%、50%、56%(均P<0.001),安慰剂组降低7%。
- 2.5和5 mg/d组UACR缓解率均为21%,安慰剂组为3%(均P<0.05)。
- Esaxerenone组不良事件略多于安慰剂,但0.625、1.25、2.5 mg/d组药物相关不良事件和停药率与安慰剂相似;5 mg/d组药物相关不良事件和停药略高。
- 最常见药物相关不良事件为高钾血症,呈剂量比例性。
关键数值与推荐
- UACR缓解定义为治疗结束时UACR<30 mg/g且较基线下降≥30%。
临床怎么用
- 对于已接受RAS抑制剂治疗但仍有微量白蛋白尿的2型糖尿病患者,可考虑加用Esaxerenone 1.25–2.5 mg/d以降低白蛋白尿,并监测血钾。
局限性
- 研究为II期试验、样本量365例、治疗仅12周,长期肾脏保护效应未评估。
- 研究人群为日本患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The progression of kidney disease in some patients with type 2 diabetes mellitus may not be adequately suppressed by renin-angiotensin system inhibitors. Esaxerenone (CS-3150) is a nonsteroidal mineralocorticoid receptor blocker that has shown kidney protective effects in preclinical studies, and it is a potential add-on therapy to treat diabetic kidney disease. This phase 2 study evaluated the efficacy and safety of esaxerenone in Japanese patients with type 2 diabetes mellitus and microalbuminuria. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This multicenter, randomized, double-blind, placebo-controlled trial enrolled 365 hypertensive or normotensive patients with type 2 diabetes mellitus and microalbuminuria (urinary albumin-to-creatinine ratio ≥45 to <300 mg/g creatinine) treated with renin-angiotensin system inhibitor who had eGFR≥30 ml/min per 1.73 m2. Participants were randomized to receive 0.625, 1.25, 2.5, or 5 mg/d esaxerenone or placebo for 12 weeks. The primary end point was the change in urinary albumin-to-creatinine ratio from baseline to week 12 (with last observation carried forward). RESULTS: Esaxerenone treatment at 1.25, 2.5, and 5 mg/d significantly reduced urinary albumin-to-creatinine ratio by the end of treatment (38%, 50%, and 56%, respectively) compared with placebo (7%; all P<0.001). The urinary albumin-to-creatinine ratio remission rate (defined as urinary albumin-to-creatinine ratio <30 mg/g creatinine at the end of treatment and ≥30% decrease from baseline) was 21% in the 2.5- and 5-mg/d groups versus 3% for placebo (both P<0.05). Adverse events occurred slightly more frequently with esaxerenone versus placebo, but the frequencies of drug-related adverse events and discontinuation rates were similar in the placebo and the 0.625-, 1.25-, and 2.5-mg/d groups. Drug-related adverse events and treatment discontinuations were marginally higher in the 5-mg/d group. The most common drug-related adverse event was hyperkalemia, which was dose proportional. CONCLUSIONS: Adding esaxerenone at 1.25, 2.5, and 5 mg/d for 12 weeks to an ongoing renin-angiotensin system inhibitor significantly reduces urinary albumin-to-creatinine ratio in patients with type 2 diabetes mellitus and microalbuminuria.
引用
- Ito S, Shikata K, Nangaku M, et al. Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Clin J Am Soc Nephrol. 2019. PMID: 31248950. doi:10.2215/CJN.14751218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。